Postoperative chemo–endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor–positive stage II breast cancer

被引：0
作者：
Keizo Sugimachi
Yoshihiko Maehara
Kohei Akazawa
Yasuo Nomura
Kazuyuki Eida
Michio Ogawa
Eiji Konaga
Noriaki Tanaka
Tetsuya Toge
Kiyohiko Dohi
Shoichihi Noda
Masazumi Maeda
Yasumasa Monden
机构：
[1] Kyushu University,Department of Surgery II, Faculty of Medicine
[2] Kyushu University,Department of Medical Informatics, Faculty of Medicine
[3] National Kyushu Cancer Center Hospital,Department of Surgery II
[4] Nagasaki Red Cross Hospital,Department of Surgery I
[5] Kumamoto University Medical School,The Department of Surgery, Research Institute for Nuclear Medicine and Biology
[6] National Iwakuni Hospital,Department of Surgery II
[7] Okayama University Medical School,Department of Surgery II
[8] Hiroshima University,Department of Surgery II, School of Medicine
[9] Hiroshima University School of Medicine,undefined
[10] National Beppu Hospital,undefined
[11] Kagawa Medical University,undefined
[12] The University of Tokushima,undefined
来源：
Breast Cancer Research and Treatment | 1999年 / 56卷 / 2期
关键词：
breast cancer; estrogen receptor; mitomycin C; postoperative chemotherapy; tamoxifen; UFT;
D O I：
10.1023/A:1006221425652
中图分类号：
学科分类号：
摘要：
The effectiveness of combining mitomycin C (MMC), tamoxifen (TAM), and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) was evident in patients with estrogen receptor-positive (ER+) breast cancers. UFT, an oral preparation of tegafur and uracil at a molar ratio of 1:4, was reported to have higher antitumor effects than tegafur alone for patients with breast cancer. Therefore, the combined chemotherapy of MMC, TAM and UFT may possibly be effective for breast cancer.
引用
收藏
页码：111 / 122
页数：11
相关论文
共 185 条
  • [1] Pritchard KI(1985)Current status of adjuvant endocrine therapy for resectable breast cancer JAMA 254 3461-3463
  • [2] Goldhirsch AG(1987)Meeting highlights: International consensus panel on the treatment of primary breast cancer Semin Oncol 14 23-33
  • [3] Wood WC(1995)The biology and physiology of 'Nolvadex' _(tamoxifen) in the treatment of breast cancer J Natl Cancer Inst 87 1441-1445
  • [4] Senn H-J(1982)Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Projects B-16 Breast Cancer Res Treat 2 363-374
  • [5] Glick JH(1988)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer New Engl J Med 319 1681-1691
  • [6] Gelber RD(1990)Chemotherapy with mitomycin-C and cyclophosphamide adjuvant to surgery for breast cancer J Clin Oncol 8 1005-1018
  • [7] Patterson I(1992)Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer Lancet 339 1-15
  • [8] Furr B(1995)Effect of uracil on metabolism of 5-fluorouracil New Engl J Med 332 901-906
  • [9] Wakeling A(1979)Metabolism of 5-fluorouracil in various human normal and tumor tissues Jpn J Clin Oncol 9 27-34
  • [10] Battersby L(1980)Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity Cancer 46 2373-2379
12345678910